CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Sells $11,707.20 in Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Marcia Belvin sold 19,512 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $0.60, for a total value of $11,707.20. Following the completion of the sale, the senior vice president now owns 248,636 shares in the company, valued at approximately $149,181.60. This represents a 7.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

CytomX Therapeutics Stock Up 0.1 %

Shares of CytomX Therapeutics stock opened at $0.67 on Friday. CytomX Therapeutics, Inc. has a fifty-two week low of $0.56 and a fifty-two week high of $5.85. The firm has a market cap of $53.41 million, a PE ratio of 3.92 and a beta of 1.05. The business’s fifty day moving average is $0.76 and its two-hundred day moving average is $0.98.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.45. The business had revenue of $38.09 million for the quarter, compared to analyst estimates of $13.53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. Equities research analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on CTMX. HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, March 7th. StockNews.com upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, March 10th. Finally, Wedbush reiterated an “outperform” rating and set a $5.00 target price on shares of CytomX Therapeutics in a report on Friday, March 7th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $5.02.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. FMR LLC raised its position in shares of CytomX Therapeutics by 17.3% in the 3rd quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock worth $335,000 after buying an additional 41,949 shares during the period. Geode Capital Management LLC raised its position in shares of CytomX Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after buying an additional 34,032 shares during the period. Virtu Financial LLC purchased a new position in shares of CytomX Therapeutics in the 3rd quarter worth $104,000. Miller Financial Services LLC purchased a new position in shares of CytomX Therapeutics in the 4th quarter worth $26,000. Finally, Traphagen Investment Advisors LLC purchased a new position in shares of CytomX Therapeutics in the 4th quarter worth $31,000. 67.77% of the stock is owned by hedge funds and other institutional investors.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.